Changes in Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Over Time in 10 Sites in the United States, March-August, 2020.
Travis LimMark DeloreyNicolette BestulMichael A JohannsonCarrie ReedAron J HallAlicia M FryChris EdensVera SemenovaHan LiPeter BrowningRita DesaiMonica EppersonTao JiaNatalie J ThornburgJarad SchifferFiona P HaversPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021)
Estimated seroprevalence was low in most sites, indicating that most people in the United States had not been infected with SARS-CoV-2 as of July 2020. The majority of infections are likely not reported. Decreases in seroprevalence may be related to changes in healthcare-seeking behavior, or evidence of waning of detectable anti-SARS-CoV-2 antibody levels at the population level. Thus, seroprevalence estimates may underestimate the cumulative incidence of infection.